Randomised Evaluation of COVID-19 Therapy (RECOVERY)
Severe Acute Respiratory Syndrome
About this trial
This is an interventional treatment trial for Severe Acute Respiratory Syndrome focused on measuring COVID-19, SARS-CoV-2, SARS coronavirus 2, SARS, Viral pneumonia syndrome
Eligibility Criteria
Inclusion Criteria:
- (i) Hospitalised
- (ii) Viral pneumonia syndrome
In general, viral pneumonia should be suspected when a patient presents with:
- typical symptoms (e.g. influenza-like illness with fever and muscle pain, or respiratory illness with cough and shortness of breath); and
- compatible chest X-ray findings (consolidation or ground-glass shadowing); and
- alternative causes have been considered unlikely or excluded (e.g. heart failure, bacterial pneumonia).
However, the diagnosis remains a clinical one based on the opinion of the managing doctor.
- (iii) SARS-CoV-2 infection (clinically suspected or laboratory confirmed)
- (iv) No medical history that might, in the opinion of the attending clinician, put the patient at significant risk if he/she were to participate in the trial
Exclusion Criteria:
- If the attending clinician believes that there is a specific contra-indication to one of the active drug treatment arms (see Protocol Appendix 2; section 8.2 and Appendix 3; section 8.3 for children) or that the patient should definitely be receiving one of the active drug treatment arms then that arm will not be available for randomisation for that patient. For patients who lack capacity, an advanced directive or behaviour that clearly indicates that they would not wish to participate in the trial would be considered sufficient reason to exclude them from the trial.
Sites / Locations
- MRC Unit The Gambia at LSHTM, Atlantic Boulevard, Fajara P. O. Box 273
- Kumasi Center for Collaborative Research in Tropical Medicine KNUSTRecruiting
- Indian Council of Medical Research, Division of Epidemiology and Communicable DiseasesRecruiting
- Eijkman Oxford Clinical Research Unit (EOCRU), Eijkman Institute for Molecular BiologyRecruiting
- Clinical Trial Unit, Oxford University Clinical Research Unit-Nepal, Patan Academy of Health SciencesRecruiting
- Wits Health ConsortiumRecruiting
- RECOVERY Sri Lanka & Pakistan, National Intensive Care Surveillance - M.O.R.U
- Nuffield Department of Population Health, University of OxfordRecruiting
- Oxford University Clinical Research Unit, Centre for Tropical MedicineRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Arm 7
Arm 8
Arm 9
Arm 10
Arm 11
Arm 12
Arm 13
Arm 14
Arm 15
Arm 16
Arm 17
Arm 18
Arm 19
No Intervention
Active Comparator
Active Comparator
Active Comparator
Active Comparator
Active Comparator
Active Comparator
Active Comparator
Active Comparator
Active Comparator
Active Comparator
Active Comparator
Active Comparator
Active Comparator
Active Comparator
Active Comparator
Active Comparator
Active Comparator
Active Comparator
Standard Care
Low dose corticosteroids
Hydroxychloroquine
Lopinavir-Ritonavir
Azithromycin
Convalescent plasma
Tocilizumab
Intravenous Immunoglobulin
Synthetic neutralising antibodies
Aspirin
Colchicine
Baricitinib
Anakinra
Dimethyl fumarate
High Dose Corticosteroids
Empagliflozin
Sotrovimab
Molnupiravir
Paxlovid
Patient receives usual hospital care
First (main) randomisation part A [This arm is now closed to recruitment]
First (main) randomisation part A [This arm is now closed to recruitment]
First (main) randomisation part A [This arm is now closed to recruitment]
First (main) randomisation part A [This arm is now closed to recruitment]
First (main) randomisation part B [This arm is now closed to recruitment]
Participants with progressive COVID-19 (as evidenced by hypoxia and an inflammatory state) may undergo randomisation between Tocilizumab and no additional treatment. (Children with COVID-19 pneumonia are not eligible for this comparison). [This arm is now closed to recruitment]
First (main) randomisation part A (children only) [This arm is now closed to recruitment]
First (main) randomisation part B. [This arm is now closed to recruitment]
First (main) randomisation part C [This arm is now closed to recruitment]
First (main) randomisation part A [This arm is now closed to recruitment]
First (main) randomisation part D [This arm is now closed to recruitment]
Randomisation for children only with PIMS-TS (Children with COVID-19 pneumonia are not eligible for this comparison). [This arm is now closed to recruitment]
First (main) randomisation part A (UK adults only; early phase assessment) [This arm is now closed to recruitment]
First (main) randomisation part E
First (main) randomisation part F
First (main) randomisation part J
First (main) randomisation part K
First (main) randomisation part L